Lyfgenia (lovotibeglogene autotemcel) prior authorization form and requirements
Customize your policy alerts
Sign up for all Geisinger Health Plan policy alerts
Know when Geisinger Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization form and requirements for Lyfgenia (lovotibeglogene autotemcel) for Geisinger Health Plan members; directed to prescribers and service providers submitting requests for this gene therapy.
No material clinical or coverage changes in this revision.
Coverage Criteria — Eligibility and Exclusions
Initial therapy / eligibility
Covered when ALL of the following are met (checkboxes on the form must be selected and documentation submitted):
Each item corresponds to a required checkbox on the form.
Form requires documentation of the event(s) and associated clinical records (e.g., ED or hospital visits) as applicable.
The checklist on the prior authorization form includes an explicit exclusion: the patient must not have received a prior allogeneic hematopoietic stem cell transplant. The form provides a checkbox for the prescriber to confirm this; if that box is not checked (indicating a prior allogeneic transplant), the request does not meet this coverage criterion and should be handled as excluded per the form.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.